Intervacc AB

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:59:30 07/06/2024 pm IST			5-day change	1st Jan Change
3.42 ^SEK	-7.57%		-12.53%	-45.97%

15/05	Intervacc AB Announces Board Appointments	CI
15/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Intervacc AB Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

October 12, 2022 at 05:01 pm IST

Intervacc AB (publ) announced that the first batch of Strangvac for sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands has been released.

Latest news about Intervacc AB

Intervacc AB Announces Board Appointments	15/05	CI
Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Intervacc AB Announces Changes in the Nomination Committee	04/03	CI
Intervacc's Acting CEO Assumes Role Permanently	28/02	MT
Jonas Sohlman Appoints as New CEO for Intervacc AB	28/02	CI
Intervacc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/02	CI
Intervacc AB Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
Intervacc, Moredun Scientific Receive Eurostars Grant for Vaccine Against Pig Infection	08/02	MT
Intervacc AB Awards Prestigious Eurostars Grant to Advance Their New Prototype Vaccine Against Streptococcus Suis Infection in Pigs	08/02	CI
Intervacc AB Announces Changes in the Nomination Committee	21/12	CI
Intervacc AB Announces Executive Changes	23/11	CI
Intervacc Secures US Patent for Vaccine Against Infectious Disease Targeting Pigs	23/11	MT
Intervacc AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
Intervacc AB Announces Composition of Nomination Committee	31/23/31	CI
Intervacc AB(OM:IVACC) dropped from S&P Global BMI Index	18/23/18	CI
Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/23/31	CI
Intervacc President, CEO Resigns; Interim Successor Named	21/23/21	MT
Intervacc AB Announces Executive Changes	21/23/21	CI
Intervacc AB Announces Executive Changes	21/23/21	CI
Intervacc AB Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova	17/23/17	CI
Swedish Animals Vaccine Maker Intervacc Partners With Testa Center	11/23/11	MT
Intervacc to Collaborate with Testa Center to Optimise Production Processes for Their Prototype Vaccine for Pigs	11/23/11	CI
Intervacc AB Approves the Election of Boel Sundvall as Board Member	08/23/08	CI
The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months	17/23/17	CI
Veterinary Medicines Directorate Extends the Shelf Life for Intervacc AB's Strangvac, a Vaccine Against Equine Strangvac, to 33 Months	08/23/08	CI

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâs candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Intervacc AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INTERVACC AB	-45.97%	2.46Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	12TCr
REGENERON PHARMACEUTICALS, INC.	+14.19%	11TCr
BIONTECH SE	-4.93%	2.42TCr
ARGENX SE	+3.23%	2.28TCr
GENMAB A/S	-10.44%	1.8TCr
WUXI APPTEC CO., LTD.	-41.74%	1.64TCr
BEIGENE, LTD.	-13.31%	1.64TCr
NEUROCRINE BIOSCIENCES, INC.	+2.44%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+27.89%	1.17TCr

Bio Therapeutic Drugs

Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Intervacc AB Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

Latest news about Intervacc AB

Chart Intervacc AB

Company Profile

Income Statement Evolution

Ratings for Intervacc AB

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs